Finally, PPARγ antagonism by using PPARγ antagonist GW9662, largely ameliorates body weight gain and hepatic steatosis in HFD-fed RORαLKO mice, indicating that dysregulated PPARγ signaling is a critical metabolic cue, leading to metabolic defects in HFD-fed RORαLKO mice. This evidence concerns the gene PPARG and Hepatic steatosis.